MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Semaglutide Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Semaglutide (Novo Nordisk's Ozempic, Wegovy and oral Rybelsus) is a once-weekly GLP-1 receptor agonist — the most clinically validated incretin in the obesity and type 2 diabetes literature. GLP-1 receptor activation in hypothalamic POMC and arcuate neurons suppresses appetite, slows gastric emptying and enhances glucose-dependent insulin secretion. In the pivotal STEP-1 trial (Wilding et al., NEJM 2021), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks, and the SELECT cardiovascular outcomes trial (Lincoff et al., NEJM 2023) demonstrated a 20% reduction in major adverse cardiovascular events in patients with obesity and established cardiovascular disease without diabetes [1][3]. FDA approved for type 2 diabetes (2017 Ozempic, 2019 Rybelsus) and chronic weight management (Wegovy, June 2021), with subsequent label expansions to cardiovascular risk reduction (2024) and chronic kidney disease in T2D.
Reconstitute: Add 2 mL bacteriostatic water → 2.5 mg/mL concentration.
Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL = 0.0250 mg (25 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen at −20 °C; reconstituted refrigerated at 2–8 °C; use within 28 days; avoid repeated freeze–thaw cycles.
Half-life: Approximately 165 hours (around 7 days), driven by C18 fatty-diacid acylation and reversible albumin binding — supports stable steady-state on once-weekly subcutaneous dosing [2].
Approval status: FDA approved as Ozempic (T2D, 2017), Rybelsus (oral T2D, 2019), Wegovy (obesity, 2021). Label expanded in 2024 for MACE reduction in obesity without diabetes based on SELECT.
Cardiovascular outcome: SELECT (NEJM 2023) showed a 20% relative reduction in 3-point MACE in 17,604 adults with obesity and prior CV disease — the first obesity drug with proven CV benefit independent of glycemia [3].
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall to minimize foaming; avoid shaking.
Gently swirl or roll the vial until the powder is fully dissolved.
Inject slowly and steadily; wait a few seconds before withdrawing the needle to ensure complete delivery.
Interactive Semaglutide Syringe Calculator
Currently visualizing the 5 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 5mg dry powder in 2mL water yields 2.50 mg/mL. To evaluate a 250mcg dose, pull to 10.0 units (10 syringe ticks).
U-100 Syringe Representation
10.0 Units (10 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Weekly Dose | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 250 mcg (0.25 mg) | 10 units (0.10 mL) |
| Weeks 5–8 | 500 mcg (0.5 mg) | 20 units (0.20 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 40 units (0.40 mL) |
| Weeks 13–16 | 1700 mcg (1.7 mg) | 68 units (0.68 mL) |
| Weeks 17+ (Maintenance) | 2400 mcg (2.4 mg) | 96 units (0.96 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 5 mg vial.
Peptide Vials (Semaglutide, 5 mg each):
- check8 weeks ≈ 1 vial (3 mg total used)
- check12 weeks ≈ 2 vials (7 mg total used)
- check16 weeks ≈ 3 vials (13.8 mg total used)
- check20 weeks ≈ 5 vials (23.4 mg total used with maintenance dosing)
Insulin Syringes (U-100):
- checkPer week: 1 syringe
- check8 weeks: 8 syringes
- check12 weeks: 12 syringes
- check16 weeks: 16 syringes
- check20 weeks: 20 syringes
Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial for reconstitution. Note: Use bacteriostatic water within 28 days after opening[9].
- check8 weeks (1 vial): 2 mL → 1 × 10 mL bottle
- check12 weeks (2 vials): 4 mL → 1 × 10 mL bottle
- check16 weeks (3 vials): 6 mL → 1 × 10 mL bottle
- check20 weeks (5 vials): 10 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each week.
- checkPer week: 2 swabs
- check8 weeks: 16 swabs
- check12 weeks: 24 swabs
- check16 weeks: 32 swabs
- check20 weeks: 40 swabs → recommend 1 × 100-count box
Mechanism of Action (MOA)
Semaglutide is a 31-amino-acid synthetic analogue of human GLP-1 in which substitution at position 8 (alanine to α-aminoisobutyric acid) blocks DPP-4 enzymatic degradation and a C18 fatty-diacid linker at position 26 promotes reversible binding to serum albumin, yielding a terminal half-life of approximately 7 days and supporting fixed weekly subcutaneous administration [1][2]. The drug acts as a full agonist at the GLP-1 receptor, distributed across the central nervous system (arcuate nucleus, brainstem area postrema), pancreatic beta-cells, gastric and intestinal smooth muscle, and the cardiovascular system. Activation of central GLP-1 receptors reduces hunger and increases satiety through engagement of POMC neurons and inhibition of AgRP signaling. Peripheral receptor binding slows gastric emptying — measurable by paracetamol-absorption test — which prolongs sensations of fullness, and stimulates glucose-dependent insulin secretion while suppressing glucagon release from pancreatic alpha-cells. The injection is administered subcutaneously in the abdomen, thigh or upper arm using a multi-dose pen device. Dose-proportional pharmacokinetics are observed across the 0.25–2.4 mg range. Steady-state plasma concentrations are reached after about 4–5 weeks of constant dosing. The titration protocol used in STEP-1 and the Wegovy label is designed to mitigate gastrointestinal effects: 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks and finally 2.4 mg as maintenance — a 16-week ramp. The Ozempic T2D protocol stops at 1.0 mg or 2.0 mg. The oral formulation (Rybelsus) uses the absorption enhancer SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) and requires fasting administration with no more than 4 oz of water and a 30-minute pre-meal window. Downstream metabolic effects extend well beyond glucose lowering and weight loss [3]. The SELECT cardiovascular-outcomes trial of 17,604 adults with established CVD and obesity but without diabetes showed semaglutide 2.4 mg reduced 3-point MACE (cardiovascular death, non-fatal MI, non-fatal stroke) by 20% over a mean 39.8 months [3]. The STEP-HFpEF program demonstrated improvements in heart-failure symptoms and 6-minute walk distance in obese HFpEF patients. The FLOW trial showed a 24% reduction in major kidney outcomes in patients with T2D and chronic kidney disease. In addition to these renal and cardiovascular benefits, semaglutide produces meaningful reductions in liver fat, fasting triglycerides, apolipoprotein B and systolic blood pressure (5–6 mmHg). Mechanistic studies suggest direct anti-inflammatory effects in vascular endothelium and reduction of low-grade systemic inflammation as quantified by hsCRP.
Clinical Trial Efficacy Highlights
- starSTEP-1 (Wilding et al., NEJM 2021) randomized 1,961 adults with overweight or obesity without diabetes to semaglutide 2.4 mg weekly or placebo plus lifestyle intervention for 68 weeks. Mean weight reduction was 14.9% on semaglutide vs 2.4% with placebo, with 50.5% achieving ≥15% loss and 32% achieving ≥20% loss [1].
- starSTEP-2 (Davies et al., Lancet 2021) studied 1,210 adults with overweight or obesity AND type 2 diabetes. Semaglutide 2.4 mg produced 9.6% mean weight reduction at 68 weeks versus 3.4% with placebo — smaller than in non-diabetics but still clinically meaningful, with concurrent HbA1c reduction of 1.6% [4].
- starSTEP-3 (Wadden et al., JAMA 2021) added intensive behavioral therapy to semaglutide and produced 16.0% mean weight loss at 68 weeks vs 5.7% with placebo plus behavioral therapy, showing additive benefit from combining drug and behavioral approaches [5].
- starSTEP-4 (Rubino et al., JAMA 2021) demonstrated that continued semaglutide 2.4 mg from week 20 onward maintained an additional 7.9% weight loss, while patients switched to placebo regained 6.9% — confirming continued therapy is required for sustained benefit [6].
- starSTEP-5 (Garvey et al., Nat Med 2022) showed durability over 104 weeks (2 years), with semaglutide-treated participants maintaining a 15.2% mean weight loss compared to 2.6% on placebo — addressing concerns about pharmacologic plateau and rebound.
- starSELECT (Lincoff et al., NEJM 2023) randomized 17,604 adults with established CVD and BMI ≥27 (without diabetes) to semaglutide 2.4 mg or placebo. The composite of CV death, non-fatal MI or non-fatal stroke fell by 20% (HR 0.80; 95% CI 0.72–0.90) over a mean 39.8 months, the first cardiovascular outcomes trial in obesity to reach significance [3].
- starFLOW (Perkovic et al., NEJM 2024) showed semaglutide 1.0 mg weekly reduced major kidney outcomes (composite of kidney failure, ≥50% eGFR decline or renal/CV death) by 24% in adults with T2D and chronic kidney disease — leading to a new renal indication.
- starReal-world cohort analyses confirm 10–13% average weight loss in clinical practice at 12 months, modestly below the STEP trial average — driven by lower titration completion rates and adherence.
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningGastrointestinal events are the dominant side effect: nausea 44% (vs 16% placebo), diarrhea 32%, vomiting 24% and constipation 24% in STEP-1. Most events were mild-to-moderate, concentrated during titration and resolved within 1–2 weeks of dose stabilization; 4.5% discontinued for GI reasons [1].
- warningCholelithiasis and acute cholecystitis occurred in 2.6% on semaglutide vs 1.2% on placebo in pooled STEP data — a recognized class effect of rapid weight loss and altered bile-flow dynamics. Patients should be counseled on right-upper-quadrant pain warning signs [1].
- warningAcute pancreatitis remains a label concern, with an absolute event rate <0.4% in STEP trials, broadly consistent with background population rates. The FDA label advises discontinuation if pancreatitis is suspected and avoidance in patients with a history of pancreatitis.
- warningHeart-rate elevation of 2–4 beats per minute on average was observed in STEP-1; clinical significance appears minimal but pre-existing tachyarrhythmia warrants caution. No QT prolongation was identified.
- warningHypoglycemia is uncommon as monotherapy because GLP-1 receptor activation is glucose-dependent, but rates increase substantially when combined with sulfonylureas or insulin — these background therapies should typically be dose-reduced.
- warningFDA labeling includes a boxed warning for medullary thyroid carcinoma based on rodent C-cell carcinogenicity data; semaglutide is contraindicated in patients with a personal or family history of MTC or MEN-2 syndrome. No clear human signal has emerged from post-marketing surveillance.
- warningInjection-site reactions (erythema, pruritus) occur in approximately 1–3% of participants, almost always mild and self-limited with site rotation.
- warningEmerging case reports describe non-arteritic anterior ischemic optic neuropathy (NAION) with semaglutide; a 2024 Harvard pharmacoepidemiology analysis suggested an elevated relative risk in T2D, though absolute incidence remains low and causality is unproven.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Semaglutide dosage?expand_more
For weight management (Wegovy), titrate weekly subcutaneously: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg, increasing every 4 weeks to reach maintenance at week 16. For type 2 diabetes (Ozempic), titration stops at 0.5 mg, 1.0 mg or 2.0 mg as needed for HbA1c goals. Oral Rybelsus dosing is 3 mg → 7 mg → 14 mg daily.
How is Semaglutide different from Tirzepatide?expand_more
Semaglutide is a pure GLP-1 receptor agonist; tirzepatide is a dual GLP-1/GIP receptor agonist. In SURPASS-2, tirzepatide 15 mg beat semaglutide 1 mg on HbA1c and weight loss. Cross-trial estimates put tirzepatide at ~21% weight loss vs semaglutide ~15%. Semaglutide has SELECT cardiovascular outcomes data, tirzepatide does not yet.
What are the most common side effects of Semaglutide?expand_more
Most common are GI: nausea (44%), diarrhea (32%), vomiting (24%) and constipation (24%), concentrated during titration. Other notable events: gallbladder disease (2.6%), small heart-rate increase, and rare pancreatitis. The label carries a boxed warning for thyroid C-cell tumors based on rodent data only [1].
How should Semaglutide be reconstituted and stored?expand_more
Wegovy and Ozempic pens are pre-filled — store at 2–8 C, protect from light, may be kept at room temperature (up to 30 C) for 28 days once in use. Compounded vials reconstituted with bacteriostatic water should be refrigerated and used within 28 days. Do not freeze; discard if cloudy or discolored. Rybelsus tablets store at room temperature.
Is Semaglutide FDA approved?expand_more
Yes. FDA approved Ozempic (subcutaneous, T2D) in December 2017, Rybelsus (oral, T2D) in September 2019, Wegovy (subcutaneous, chronic weight management) in June 2021, and a Wegovy label expansion for cardiovascular risk reduction in adults with obesity and established CVD in March 2024 based on SELECT [3].
Academic References & Study Citations
Wilding JPH, Batterham RL, Calanna S, et al. (2021) N Engl J Med 384:989-1002. 'Once-Weekly Semaglutide in Adults with Overweight or Obesity' (STEP-1). 14.9% weight loss at 68 weeks on 2.4 mg. View Scientific Paper →
Lau J, Bloch P, Schaffer L, et al. (2015) J Med Chem 58:7370-7380. 'Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide'. View Scientific Paper →
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023) N Engl J Med 389:2221-2232. 'Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes' (SELECT). 20% MACE reduction. View Scientific Paper →
Davies M, Faerch L, Jeppesen OK, et al. (2021) Lancet 397:971-984. 'Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)'. View Scientific Paper →
Wadden TA, Bailey TS, Billings LK, et al. (2021) JAMA 325:1403-1413. 'Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight (STEP-3)'. View Scientific Paper →
Rubino D, Abrahamsson N, Davies M, et al. (2021) JAMA 325:1414-1425. 'Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP-4)'. View Scientific Paper →
Garvey WT, Batterham RL, Bhatta M, et al. (2022) Nat Med 28:2083-2091. 'Two-year effects of semaglutide in adults with overweight or obesity (STEP-5)'. View Scientific Paper →
Perkovic V, Tuttle KR, Rossing P, et al. (2024) N Engl J Med 391:109-121. 'Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes' (FLOW). View Scientific Paper →
Kosiborod MN, Abildstrom SZ, Borlaug BA, et al. (2023) N Engl J Med 389:1069-1084. 'Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity' (STEP-HFpEF). View Scientific Paper →
FDA label — Wegovy (semaglutide) injection, full prescribing information, updated March 2024. View Scientific Paper →